Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness
Seminars in Thrombosis and Hemostasis · 01.04.2026 · 52 (03) · 362-364
DOI: 10.1055/a-2691-6232 ↗Kurz gefasst
Fachartikel in der Zeitschrift Seminars in Thrombosis and Hemostasis, erschienen am 01.04.2026. Verfasst von Gerard Gurumurthy und 5 weiteren Autor:innen. Beteiligte Einrichtung: The University of Manchester, Manchester, United Kingdom. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- The University of Manchester, Manchester, United Kingdom.
- Department of Paediatric Haematology, Royal Manchester Children's Hospital, Manchester, United Kingdom.
- Department of Haematology, Manchester Royal Infirmary, Manchester, United Kingdom.
- Department of Cardiovascular Sciences, The University of Manchester, Manchester, United Kingdom.
Zitieren
APA
Gurumurthy, G., Reynolds, L., Scott, M., Davies, E., Hay, C., & Thachil, J. (2026). Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness. Seminars in Thrombosis and Hemostasis, 52(03), 362-364. https://doi.org/10.1055/a-2691-6232
Vancouver
Gurumurthy G, Reynolds L, Scott M, Davies E, Hay C, Thachil J. Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness. Seminars in Thrombosis and Hemostasis. 2026;52(03):362-364. doi:10.1055/a-2691-6232
BibTeX
@article{Gurumurthy2026,
author = {Gurumurthy, Gerard and Reynolds, Lianna and Scott, Martin and Davies, Elizabeth and Hay, Charles and Thachil, Jecko},
title = {Emicizumab in Acquired Hemophilia A: Benefits in Bleed Control, Safety, and Cost-Effectiveness},
journal = {Seminars in Thrombosis and Hemostasis},
year = {2026},
volume = {52},
number = {03},
pages = {362--364},
doi = {10.1055/a-2691-6232}
}
EUVIMED